Form 8-K - Current report:
SEC Accession No. 0001193125-21-003683
Filing Date
2021-01-07
Accepted
2021-01-07 07:08:53
Documents
14
Period of Report
2021-01-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d67311d8k.htm   iXBRL 8-K 31852
2 EX-10.1 d67311dex101.htm EX-10.1 95907
3 EX-99.1 d67311dex991.htm EX-99.1 5433
  Complete submission text file 0001193125-21-003683.txt   280008

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apls-20210106.xsd EX-101.SCH 3065
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20210106_lab.xml EX-101.LAB 17372
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20210106_pre.xml EX-101.PRE 10949
7 EXTRACTED XBRL INSTANCE DOCUMENT d67311d8k_htm.xml XML 3208
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 21512979
SIC: 2834 Pharmaceutical Preparations